BERGEN BRUNSWIG ADDING $140 MIL. IN SALES VIA HEALTHCARE DISTRIBUTORS
BERGEN BRUNSWIG ADDING $140 MIL. IN SALES VIA HEALTHCARE DISTRIBUTORS of Indiana, which the whole-saler is acquiring in a deal announced Dec. 14. HDI is a privately-owned distributor covering Indiana and Illinois. The agreement to acquire substantially all of the assets of HDI at a value of approximately $14 mil. includes an exchange of stock and the assumption of certain liabilities. HDI is the latest in an extensive series of purchases by Bergen Brunswig that have broadened the wholesaler's geographical reach ("The Pink Sheet" Nov. 16, T&G-5). Bergen said its proposed purchase of South Bend-based HDI will provide it with "substantially improved" access to the Midwestern market and "complement our existing regional distribution center in Williamston, Mich." The transaction is expected to be completed in January, "subject to regulatory and other approvals." Bergen also announced that it has decided to retain and develop the medical supply business of Durr-Fillauer, rather than sell it as previously indicated. In the wholesaler's annual report released in November, Bergen had confirmed its intention to sell the medical/surgical supply and orthotic divisions that had been acquired in the October purchase of Durr-Fillauer. Bergen paid well over $400 mil. for Durr-Fillauer, and the sale of the medical/surgical operations would have helped to make up some part of the cost. Durr's medical/surgical business represented about one quarter of the company's $950 mil. in total sales in 1991. However, on Dec. 16, Bergen announced that, having failed to receive an acceptable offer for the business and having assessed first quarter results and the contribution the medical business was making, the company had resolved to hold on to the business.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth